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Abstract
Background: Glucocorticoids are used to treat chronic inflammatory diseases such as asthma. Induction of
eosinophil apoptosis is considered to be one of the main mechanisms behind the anti-asthmatic effect of
glucocorticoids. Glucocorticoid binding to its receptor (GR) can have a dual effect on gene transcription.
Activated GR can activate transcription (transactivation), or by interacting with other transcription factors such
as NF-κB suppress transcription (transrepression). RU24858 has been reported to transrepress but to have little
or no transactivation capability in other cell types. The dissociated properties of RU24858 have not been
previously studied in non-malignant human cells. As the eosinophils have a very short lifetime and many of the
modern molecular biological methods cannot be used, a "dissociated steroid" would be a valuable tool to evaluate
the mechanism of action of glucocorticoids in human eosinophils. The aim of this study was to elucidate the ability
of RU24858 to activate and repress gene expression in human eosinophils in order to see whether it is a
dissociated steroid in human eosinophils.
Methods: Human peripheral blood eosinophils were isolated under sterile conditions and cultured in the
presence and/or absence RU24858. For comparison, dexamethasone and mometasone were used. We measured
chemokine receptor-4 (CXCR4) and Annexin 1 expression by flow cytometry and cytokine production by ELISA.
Apoptosis was measured by DNA fragmentation and confirmed by morphological analysis.
Results: RU24858 (1 μM) increased CXCR4 and Annexin 1 expression on eosinophils to a similar extent as
mometasone (1 μM) and dexamethasone (1 μM). Like dexamethasone and mometasone, RU24858 did suppress
IL-8 and MCP-1 production in eosinophils. RU24858 also increased spontaneous eosinophil apoptosis to a similar
degree as dexamethasone and mometasone, but unlike dexamethasone and mometasone it did not reverse IL-5-
or GM-CSF-induced eosinophil survival.
Conclusion: Our results suggest that in human eosinophils RU24858 acts as transactivator and transrepressor
like classical glucocorticoids. Thus, RU24858 seems not to be a "dissociated steroid" in primary human eosinophils
in contrast to that reported in animal cells. In addition, functionally RU24858 seems to be a less potent
glucocorticoid as it did not reverse IL-5- and GM-CSF-afforded eosinophil survival similarly to dexamethasone
and mometasone.
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Background
Eosinophils are thought to play a critical role in allergic
diseases, such as allergic rhinitis, asthma, and atopic der-
matitis.[1] In patients with asthma, activation of eosi-
nophils is thought to cause epithelial tissue injury, and
increased bronchial responsiveness.[2] Apoptosis or pro-
grammed cell death is an important feature in the resolu-
tion of pulmonary inflammation.[3,4] Unlike necrosis
which is characterized by loss of cell membrane integrity
and the uncontrolled release of harmful cellular contents,
apoptosis is characterized by formation of apoptic bodies,
which are then phagocytosed intact so there will be no
leakage of intracellular contents or activation of the
inflammatory response.[3,5] Eosinophil apoptosis is
inhibited by cytokines such as interleukin (IL)-3, IL-5 and
granulocyte-macrophage colony-stimulating factor (GM-
CSF) in vitro and in vivo.[1] In addition, we and others
have previously shown that eosinophil apoptosis is
delayed in patients with asthma or inhalant allergy.[6,7]
Glucocorticoids are potent anti-inflammatory agents for
the treatment of allergic diseases such as asthma, allergic
rhinitis, atopic dermatitis and various syndromes associ-
ated with hypereosinophilia. Enhancement of eosinophil
apoptosis and/or reversal of cytokine-induced eosinophil
survival have been reported to be one important mecha-
nism by which glucocorticoids reduce eosinophil num-
bers. [8-18] The basic mechanism of glucocorticoid
actions is that they penetrate into the cell and bind to glu-
cocorticoid receptor molecules in the cytoplasm.[19,20]
The glucocorticoid- glucocorticoid receptor (GR) complex
acts as a transcription factor, binding to specific DNA sites
in the nucleus. Within the nucleus, GR may induce gene
transcription (transactivation) by binding to specific DNA
sequences known as glucocorticoid response elements
(GREs) in the promoter-enhancer regions of steroid
responsive genes. The glucocorticoid-glucocorticoid
receptor complex may also directly interact with other
transcription factors such as nuclear factor-κB (NF-κB)
and activator protein (AP)-1 resulting in a transcriptional
down-regulation (transrepression), which is considered
currently to be a major mechanism of the anti-inflamma-
tory effect of steroids.[20,21] Despite many studies on the
ability of glucocorticoids to repress and/or activate genes
in other cell types [22-25] there are no published data on
whether transactivation and/or transrepression events
play a role in the regulation of apoptosis in human eosi-
nophils.
Based on the hypothesis that the predominant anti-
inflammatory effects of glucocorticoids derive from inhi-
bition of transcription (transrepression), whereas the met-
abolic effects, like disrupting the regulation of calcium
and glucose metabolism, derive from positive transcrip-
tional effects (transactivation), experimental glucocorti-
coids, which only act as transrepressors but not as
transactivators, have been developed. RU24858 is such a
novel glucocorticoid.[22] However the transactivation
profile of RU24858 has been controversial. Vayssiere et
al.[22] and Vanden Berghe et al.[23] demonstrated
RU24858 to be almost as effective as dexamethasone in
inducing transrepression but show little or no transactiva-
tion ability in human and murine cell lines. In contrast,
others have reported no dissociation between anti-inflam-
matory activity and side effects in vivo.[25] Differences
between human and rodent GR or in GR-associated fac-
tors has been implicated to be critical for these divergent
results.[24] However, the ability of RU24858 to dissociate
between transactivation and transrepression in non-trans-
formed primary human cells has not been described.
Whether dissociated steroids such as RU24858 have a bet-
ter safety profile in the treatment of chronic inflammatory
diseases such as asthma depends on their ability to disso-
ciate between transactivation and transrepression in non-
malignant human cells.
Primary human eosinophils are terminally differentiated,
non-dividing cells that can only be cultured for very short
periods, making these cells unsuitable for many studies
using molecular biology. Thus, a dissociative glucocorti-
coid would be a very valuable pharmacological tool to
evaluate the mechanism of action glucocorticoids in pri-
mary cells such as human eosinophils. The aim of our
study was to test whether RU24858 discriminates between
transactivation and transrepression in human eosinophils
and the functional consequences of this profile by assess-
ing its effects on eosinophil apoptosis. We measured the
induction of surface expression of Annexin I and CXCR4
as a measure of GR transactivation[26,27] ability and the
inhibition of IL-8 and MCP-1 production to define the
transrepression potential. We found that in eosinophils
RU24858 possessed transrepression capability but also
clear transactivation effects. Surprisingly, although
RU24858 did result enhanced spontaneous eosinophil
apoptosis it did not reverse cytokine-induced apoptosis
like other glucocorticoids do.
Methods
Eosinophil isolation
Eosinophils were isolated under sterile conditions as pre-
viously reported.[6,17,18,28] Before donation of blood,
all subjects gave informed consent to a study protocol
approved by the ethical committee of Tampere University
Hospital. Eosinophils were obtained from donors with
eosinophil counts ranging from upper normal to slightly
elevated. We excluded patients with hypereosinophilic
syndrome. Venous blood (50–100 ml) was collected into
10–20 ml of acid citrate dextrose anticoagulant and
hydroxyethyl starch solution. White blood cells were
obtained after removing supernatant and were overlaidJournal of Inflammation 2006, 3:10 http://www.journal-inflammation.com/content/3/1/10
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onto Ficoll and centrifuged at 700 g for 30 min at 20°C.
Mononuclear cell layer was removed and the remaining
pellet containing granulocytes and red blood cells was
washed in HBSS (Hank's Balanced Salt Solution without
Phenol Red). Red blood cells were lysed by hypotonic
lysis.
Eosinophils were purified using immunomagnetic anti-
CD16 antibody conjugated beads. Following separation,
granulocytes were washed, counted and resuspended in
300 ml of RPMI 1640 (2% fetal calf serum and 5 mM
EDTA). Cells mixed with beads were incubated at 4°C for
at least 25 min before loading onto a separation column
positioned within a magnetic field and washed with 40 ml
of RPMI 1640. The eluted eosinophils were washed and
counted using microscopic examination and diluting 10
μl cell suspension in 90 μl Kimura stain (consisting of 11
ml of 0.05% (wt/wt) toluidine blue, 0.8 ml of 0.03% light
green SF yellowish, 0.5 ml of saturated saponin, and 5 ml
of 0.07 M phosphate buffer, pH 6.4) and the purity of
eosinophil population was >99%. The eosinophils were
washed and resuspended at 1 × 106 cells/ml and cultured
(37°C, 5 % CO2) in RPMI 1640 (Dutch modification,
10% fetal calf serum and antibiotics). Granulocytes were
incubated in the presence and absence of RU24858,
mometasone and dexamethasone. All the steroids were
diluted in DMSO. The final concentration of DMSO in the
cells was 0.1%. Similar concentration of DMSO was used
in control experiments.
Flow cytometry
Eosinophils were incubated for 24 h and the expression of
CXCR4 was determined by using a PE-conjugated mAb
against CXCR4 (20 μl/106 cells). We performed flow-cyto-
metric analysis according to the instructions of the manu-
facturer and for comparison PE-conjugated isotype
control was used. The expression of Annexin I was deter-
mined by using a mAb against Annexin I (20 μl/106 cells)
and for comparison an isotype standard was used. As a
secondary antibody we used PE-conjugated anti-mouse
IgG1 monoclonal antibody according to that described by
Liu et al.[29]
Unless otherwise stated the percentage of apoptotic cells
was measured using a relative DNA fragmentation assay
in propidium iodide stained cells by flow cytometry as
previously described.[6,17,18,28] Eosinophils were incu-
bated for 40 h. The cells showing decreased relative DNA
content were considered as apoptotic.
Morphological analysis
Cells were centrifuged onto cytospin slides. After fixation
in methanol slides were stained with May-Grünwald-
Giemsa. Cells showing typical features of apoptosis such
as condensation of chromatin, nuclear coalescence and
shrinkage of the cell were considered as apoptotic.[28,30]
Cells were counted blind. We always prepared double
identical samples and from each sample 200 cells were
assessed and finally the average was calculated.
Cytokine assays
Cytokine production was induced by 1 μM ionomy-
cin.[31] Cells were incubated for 18 h and supernatants
were collected and stored at -20°C and cytokines were
measured by ELISA. The lower limits of detection were 3.9
pg/ml for MCP-1 and 4.1 pg/ml for IL-8.
Materials
RU24858 was obtained from Aventis Pharma, Romain-
ville Cedex, France and mometasone furoate was obtained
from Schering-Plough, Kenilworth, USA. Dexamethasone
The effects of RU24858, mometasone and dexamethasone  on eosinophil CXCR4 surface expression Figure 1
The effects of RU24858, mometasone and dexameth-
asone on eosinophil CXCR4 surface expression. Cells 
were stained and analyzed by using flow cytometry. A typical 
experiment showing an increase in CXCR4 expression fol-
lowing treatment of cells with mometasone, dexamethasone 
and RU24858 is indicated in (A). (B) Summary of results 
expressed as mean fluorescence intensity. Values are the 
mean ± S.E.M., n = 6. * Indicates P < 0.05, ** P < 0.01 as com-
pared with the respective control in the absence of glucocor-
ticoids.Journal of Inflammation 2006, 3:10 http://www.journal-inflammation.com/content/3/1/10
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and propidium iodide were purchased from Sigma Chem-
ical Co. (St. Louis, MO). Other reagents were obtained as
follows: antibiotics, fetal calf serum, RPMI 1640 (Gibco
BRL, Paisley, Scotland, UK), anti-CD16 microbeads and
magnetic cell separation system (Miltenyi Biotec Ltd., Sur-
rey, UK), human recombinant IL-5, GM-CSF and DuoSet
ELISA Development System for IL-8 and MCP-1 (R&D sys-
tem Europe, Abingdon, UK), May-Grünwald (Merck,
Darmstadt, Germany), and Giemsa (J.T. Baker, Deventer,
Holland). PE-conjugated CXCR4 mAb (12G5), R-PE-con-
jugated IgG2a isotype control, Annexin I mAb, IgG1 isotype
standard and R-PE-conjugated anti-mouse IgG1 mono-
clonal antibody were all purchased from BD Pharmingen
(Temse, Belgium).
Statistics
Data are expressed as mean ± SEM. Differences were ana-
lyzed by analysis of variance supported by Student-New-
man-Keuls test and were considered significant if P < 0.05.
Results
The effect of RU24858 on CXCR4 expression on the 
surface of eosinophils
Dexamethasone has previously been shown to induce
CXCR4 expression in human eosinophils.[27] As
expected, mometasone (1 μM) and dexamethasone (1
μM) induced CXCR4 expression in human eosinophils
(Figure 1a &1b). To our surprise RU24858 (0.01–1 μM)
also induced CXCR4 expression in a manner similar to
classical glucocorticoids (Figure 1a &1b). To exclude the
possibility that RU24858 affects the fluorescence proper-
ties of the PE-conjugated antibody, its effects were studied
on cells labelled with PE-conjugated isotype control anti-
body. RU24858 (0.01 μM–1 μM), mometasone (1 μM)
and dexamethasone (1 μM) had no effect on fluorescence
of PE-conjugated isotype control (n = 6, data not shown).
The effect of RU24858 on Annexin 1 expression on the 
surface of eosinophils
It has been recently demonstrated that glucocorticoids
induce surface expression of Annexin 1 on human eosi-
nophils.[29] To further analyse the transactivation ability
of RU24858 we investigated whether it has a similar effect
on Annexin 1 expression as mometasone and dexametha-
sone. RU24858 significantly increased Annexin 1 expres-
sion to a similar extent to that seen with mometasone and
dexamethasone (both at 1 μM) (Figure 2a &2b). In addi-
tion, mometasone (1 μM), dexamethasone (1 μM) and
RU24858 (0.01 μM–1 μM) had no effect on the fluores-
cence of isotype and/or secondary antibody controls (n =
6, data not shown).
The Effect of RU24858 on cytokine production
Glucocorticoids have previously been reported to inhibit
IL-8 and MCP-1 production in eosinophils.[31] There-
fore, to study the transrepression capability of RU24858
we measured IL-8 and MCP-1 production from superna-
tants collected from ionomycin-treated eosinophils.
Spontaneous IL-8 and MCP-1 production was low and
ionomycin (1 μM) increased MCP-1 and IL-8 production
6–10-fold (figure 3a &3b). Mometasone (1 μM) and dex-
amethasone (1 μM) inhibited IL-8 and MCP-1 generation
as expected (figure 3a &3b) as also RU24858 (1 μM) did.
The effect of RU24858 on MCP-1 production was signifi-
cantly smaller than that of dexamethasone and mometa-
sone. Mometasone was also more potent than RU24858
in inhibiting IL-8 production, whereas the difference
between dexamethasone and RU24858 did not reach sta-
tistical significance (Figure 3a &3b). Taken together, the
present data suggest that RU24858 is a non selective com-
The effects of RU24858, mometasone and dexamethasone  on eosinophil Annexin 1 surface expression Figure 2
The effects of RU24858, mometasone and dexameth-
asone on eosinophil Annexin 1 surface expression. 
Cells were stained and analyzed by using flow cytometry. A 
typical experiment showing an increase in Annexin 1 expres-
sion following treatment of cells with mometasone, dexame-
thasone and RU24858 is indicated in (A). (B) Summary of 
results expressed as mean fluorescence intensity. Values are 
the mean ± S.E.M., n = 3. * Indicates P < 0.05 as compared 
with the respective control in the absence of glucocorticoids.Journal of Inflammation 2006, 3:10 http://www.journal-inflammation.com/content/3/1/10
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The effects of RU24858, mometasone and dexamethasone on eosinophil cytokine production Figure 3
The effects of RU24858, mometasone and dexamethasone on eosinophil cytokine production. (A) IL-8 and (B) 
MCP-1. Ionomycin was used to stimulate the IL-8 and MCP-1 production in cells. IL-8 and MCP-1 were analyzed by ELISA 
based methods. Values are the mean ± S.E.M., n = 6. Results are expressed as % of stimulated eosinophils. * Indicates P < 0.05, 
** P < 0.01 and *** P < 0.001 as compared with the respective control in the absence of glucocorticoids. # Indicates P < 0.05, 
## P < 0.01 and ### P < 0.001 as compared with RU24858 (1 μM).
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pound and does not dissociate between transactivation
and transrepression in human eosinophils.
Effects of RU24858 on cytokine-afforded eosinophil 
survival
To evaluate the functional consequences of RU24858
actions, its effects on cytokine-induced eosinophil sur-
vival were measured. GM-CSF inhibited eosinophil apop-
tosis in a concentration-dependent manner (Figure 4a).
GM-CSF (0.07 pM)-stimulated eosinophil survival was
reversed by dexamethasone and mometasone (both at 1
μM) (Figure 4a). In contrast, RU24858 (1 μM) did not
reverse GM-CSF-stimulated eosinophil survival (Figure
4a). When GM-CSF was added at increasing concentra-
tions the effects of dexamethasone and mometasone
reflected their GR agonist potency (Figure 4a). At 7 pM
GM-CSF no glucocorticoid was able to attenuate eosi-
nophil survival (Figure 4a).
IL-5 has also been reported to prolong eosinophil survival
in vitro[32] and in vivo. IL-5 and GM-CSF receptors are
composed of a common β-unit, but have unique α-units.
This offers a possibility for differential signalling between
IL-5 and GM-CSF.[1] IL-5 (0.1 – 10 pM) inhibited eosi-
nophil apoptosis in a concentration-dependent manner,
and its effects were partly reversed by dexamethasone and
mometasone (figure 4b). This protection by glucocorti-
coids against IL-5-stimulated inhibition of apoptosis was
lost at high concentrations of IL-5 (10 pM) (Figure 4b,
Table 1). In contrast to dexamethasone and mometasone,
RU24858 had no effect on IL-5-induced inhibition of
eosinophil apoptosis (Figure 4b), which finding was fur-
ther confirmed by using morphological analysis (Table 1).
Taken together, in contrast to classical steroids, RU24858
does not reverse cytokine-afforded eosinophil survival.
The effects of RU24858, mometasone and dexamethasone on cytokine afforded eosinophil survival Figure 4
The effects of RU24858, mometasone and dexamethasone on cytokine afforded eosinophil survival. The effects 
of RU24858, mometasone and dexamethasone (all at 1 μM) on GM-CSF-(A) and IL-5-induced (B) eosinophil survival. Values 
are the mean ± S.E.M., n = 6. Results are expressed as percentage of apoptotic cells. * Indicates P < 0.05, ** P < 0.01 and *** P 
< 0.001 as compared with the respective control in the absence of glucocorticoids.
Table 1: The effects of RU24858, mometasone and dexamethasone on IL-5 induced human eosinophil survival. Apoptosis was analyzed 
by morphological criteria. Results are expressed as percentage of apoptotic cells. Values are the mean ± S.E.M., n = 6. * Indicates P < 
0.05, ** P < 0.01, *** P < 0.001 as compared with the respective control in the absence of glucocorticoids.
Apoptotic eosinophils (%)
Control 1 nM IL-5 10 nM IL-5
control 43.3 ± 6.7 8.1 ± 1.5 9.3 ± 2.5
RU24858 1 μM 51.9 ± 5.5 * 11.6 ± 3.4 10.8 ± 3.8
Mometasone 1 μM 63.1 ± 6.8 *** 16.0 ± 2.9 ** 10.8 ± 3.6
Dexamethasone 1 μM 60.1 ± 4.4 ** 17.1 ± 3.3 ** 7.7 ± 2.6Journal of Inflammation 2006, 3:10 http://www.journal-inflammation.com/content/3/1/10
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Effects of RU24858 on spontaneous eosinophil apoptosis
The currently used glucocorticoids enhance spontaneous
eosinophil apoptosis at clinically relevant drug concentra-
tions.[17,18] RU24858 increased spontaneous eosinophil
apoptosis in a concentration-dependent manner similarly
to that seen with dexamethasone and mometasone (Fig-
ure 5). Enhancement of spontaneous apoptosis by
RU24858, dexamethasone and mometasone furoate was
also confirmed by showing an increase in the number of
eosinophils showing the typical morphological features
of apoptotic eosinophils such as nuclear chromatin con-
densation and cell shrinkage (Table 1).
Discussion
We report here for the first time the effects of a supposed
"dissociated steroid" RU24858 in primary human cells.
All the previous studies have been made with malignant
human or murine cell lines. Our results show that the dis-
sociated glucocorticoid RU24858 acts as a transrepressor
in human eosinophils but also has transactivation capa-
bility. However, RU24858 seems to be somewhat less
potent transrepressor than classical glucocorticoids dex-
amethasone and mometasone. Functionally, RU24858 is
not able to reverse GM-CSF- or IL-5-induced eosinophil
survival and thus has lower anti-inflammatory activity as
compared with the classical glucocorticoids dexametha-
sone and mometasone.
It is currently proposed that the anti-inflammatory effects
of glucocorticoids are due to inhibition of transcription,
whereas many of the debilitating side-effects may derive
from activation of transcription. So it has been hypothe-
sised that it would be possible to separate the anti-inflam-
matory effects from the side-effects of glucocorticoids, by
developing novel compounds which could repress
inflammatory gene expression but not transactivate.
RU24858 is such a novel glucocorticoid.
In contrast to our expectations, RU24858 induced transac-
tivation in eosinophils as evidenced by increased CXCR4
and annexin 1 expression. This profile of activity is similar
to that seen with classical glucocorticoids such as dexam-
ethasone and mometasone. Interestingly, RU24858
increased CXCR4 expression at lower drug concentrations
than Annexin I expression. To characterize the transre-
pression profile of RU24858 we measured cytokine pro-
duction in eosinophils. As expected, dexamethasone,
mometasone and RU24858 repressed IL-8 and MCP-1
production. However RU24858 was less potent in inhib-
iting cytokine production than the classical glucocorti-
coids. These results suggest that in human eosinophils
RU24858 represses gene transcription as supposed, but
also has an ability to transactivate. In our efforts to further
characterize the ability of RU24858 to inhibit transcrip-
tion, several cytokines and chemokines such as IL-6,
RANTES and TNF-α reported to be suppressed by gluco-
corticoids in other cells[33,34] were measured. However,
this was not successful as ionomycin was unable to induce
the production of these cytokines in human eosinophils.
Due to the inability to transfect primary human eosi-
nophils we were unable to measure GRE- and κB-depend-
ent reporter gene activity.
In the present study, we report that RU24858 was equipo-
tent with classical glucocorticoids at inducing transactiva-
tion but was less potent at inducing transrepression. We
have recently reported that RU24858 inhibits the expres-
sion of tristetraprolin at the level of mRNA and protein
expression in J774 mouse macrophages at concentrations
used in the present study.[35] In addition, we have shown
that RU24858 inhibits LPS-induced inducible nitric oxide
(iNOS) expression and nitric oxide production in mouse
J774 macrophages and the effect of RU24858 was qualita-
tively and quantitatively similar to that of dexamethasone
at similar drug concentrations.[36] Taken together, these
results suggest that the ability of RU24858 to transactivate
or transrepress depends on the cell type and source of
cells. To the best of our knowledge, this is the first report
on the effects of RU24858 in primary human cells. Studies
in transfected cell lines can lead to anomalous conclu-
sions. The receptors but also the signalling pathways that
are present in a cell line can be different than in primary
cells and can have a crucial effect on the results.[37]
The effects of RU24858, mometasone and dexamethasone  on spontaneous eosinophil apoptosis Figure 5
The effects of RU24858, mometasone and dexameth-
asone on spontaneous eosinophil apoptosis. The 
effects of RU24858 (0.01 μM, 0.1 μM, 1 μM), mometasone 
(0.01 μM, 1 μM) and dexamethasone (0.1 μM, 1 μM) on 
spontaneous eosinophil survival. Values are the mean ± 
S.E.M., n = 6. Results are expressed as percentage of apop-
totic cells. * Indicates P < 0.05, ** P < 0.01 and *** P < 0.001 
as compared with the respective control in the absence of 
glucocorticoids.Journal of Inflammation 2006, 3:10 http://www.journal-inflammation.com/content/3/1/10
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In human and murine cell lines RU24858 has been
reported to be almost as effective as dexamethasone in
inducing transrepression but to show little or no transac-
tivation ability.[22,23] In addition, only a weak transacti-
vation in Hela cells was reported. In contrast, no
difference in transactivation was seen between pred-
nisolone and RU24858 in murine CV-1 cells.[24] In addi-
tion, no dissociation between the anti-inflammatory
activity and side effects in in vivo animal models was
reported. Thus, although it has previously been suggested
that the profile of RU24858 is divergent and may be spe-
cies and/or cell type specific, the effects of this compound
have never been reported in primary human cells. A pos-
sible explanation for these divergent dissociation abilities
of this compound is that RU24858 works as a partial ago-
nist for glucocorticoid receptor. In cells where the num-
bers of receptors or signal transduction efficiency is high it
works like a full agonist. In contrast, in cells where the
number of receptors is low or efficiency of signal transduc-
tion is poor it may produce a maximal response that is less
than that of the full agonist or it may even be an antago-
nist. Use of cells from different species can also lead to var-
iability in results, as different species demonstrate
divergent sensitivities to glucocorticoids. This may explain
why Tanigava et al.[24] reported that RU24858 is able to
transactivate in murine CV-1 cells but not in human HeLa
cells. Thus, RU24858 might act as a full agonist glucocor-
ticoid sensitive species, like mice, but in species less sensi-
tive to glucocorticoids, like man, it would have a partial
effect or even it might act as an antagonist. Another possi-
ble explanation for the conflicting results may be that one
GR mRNA can produce up to at least eight functional GR
isoforms.[38] These GR isoforms display diverse tran-
scriptional activities and the levels of these isoforms vary
among different cell types. Whether this cell type -specific
isoform profile of GR activation can explain why
RU24858 has divergent transcription profile depending
on cell type remains to be determined.
Glucocorticoids are currently the most potent anti-inflam-
matory therapy available for the treatment of
asthma.[19,20] One of the main anti-inflammatory
effects of glucocorticoids in the treatment of asthma is the
reduction in eosinophil numbers. One important mecha-
nism by which glucocorticoids reduce eosinophil num-
bers seems to be the induction of eosinophil apoptosis
and/or reversal of cytokine-afforded eosinophil sur-
vival.[11,13-15,17,18] Despite the fact that these mecha-
nisms of glucocorticoids actions have been known for
many years, the role of glucocorticoid-mediated transacti-
vation or transrepression events in the regulation of eosi-
nophil apoptosis has been unclear. Eosinophils are
terminally differentiated, short-living and non-dividing
cells that can be isolated only in low numbers. Thus, most
of the modern molecular biology methods cannot be uti-
lised to study signalling in human eosinophils. As gluco-
corticoids are known to up- or downregulate transcription
of a number of genes in other cell types, a pharmacologi-
cal tool with defined mechanism of action would be inter-
esting in studying eosinophils. The main aim of our study
was to find out if the "dissociated steroid" RU24858 could
be a potent pharmacological tool in our efforts to identify
whether the effects of glucocorticoids on eosinophil sur-
vival are due to activation of transcription or transrepres-
sion. To illustrate the problem, for example, of the 2409
genes studied in eosinophils, a total of 80 were found to
be regulated 2-fold or greater after exposure to IL-5 for 1
h. Of these 73 were up-regulated and 7 were down-regu-
lated.[39] Unfortunately, RU24858 does not dissociate
between transactivation and transrepression in human
eosinophils and thus is not suitable for evaluation of sig-
nalling in human eosinophils.
In the present study we report that RU24858 induces both
transrepression and transactivation in human eosi-
nophils. To analyze the functional consequence of this
profile, we measured the effect of RU24858 on spontane-
ous apoptosis and cytokine-afforded survival of human
eosinophils. Glucocorticoids are known to enhance spon-
taneous eosinophil apoptosis and to reverse cytokine-
induced eosinophil survival.[17,18] RU24858 enhanced
spontaneous eosinophil apoptosis, but unlike dexameth-
asone and mometasone it did not reverse IL-5- or GM-
CSF-induced eosinophil survival. The result that the effect
of dexamethasone and mometasone diminishes as the
concentration of IL-5 or GM-CSF is increased is something
that could be expected for compounds acting as "physio-
logical antagonists". Rather than reflecting a true differ-
ence in the transactivation or transrepression profile
between RU24858 and dexamethasone, the lack of effect
of RU24858 on cytokine-induced eosinophil survival may
be due to the partial agonistic properties and lower
potency of RU24858 as compared with dexamethasone.
However, as RU24858 does not reverse cytokine-induced
survival of human eosinophils to a significant extent, it
can be expected to be less potent in the treatment of
asthma than the currently used glucocorticoids.
Conclusion
In conclusion, we report here for the first time that
RU24858 does not dissociate between transactivation and
transrepression in non-malignant human cells, eosi-
nophils.
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